361 Capital’s Travere Therapeutics TVTX Stock Holding History

361 Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$886K	Buy	+43,408	New	+$691K	0.42%	72

Other funds holding TVTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

361 Capital's TVTX Position: Q2 2020 in Review

361 Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2020: 43,408 shares worth $886K. The stake represents 0.42% of the portfolio and ranks #72 among its holdings.

147 funds tracked by Wall St. Rank hold TVTX as of Q2 2020.

361 Capital held 43,408 shares of Travere Therapeutics worth $886K as of Q2 2020.
Travere Therapeutics was a new 361 Capital position in Q2 2020.
Travere Therapeutics made up 0.42% of 361 Capital's portfolio in Q2 2020, its #72 holding.
147 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.